UCB Reinforces Commitment to Rheumatology With 15 Abstracts

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence...

Related Keywords

United Kingdom , Brussels , Bruxelles Capitale , Belgium , Philadelphia , Pennsylvania , United States , Smyrna , Izmir , Turkey , Great Britain , Nicole Herga , Emmanuel Caeymaex , J Clin Pharmacol , Antje Witte , Immunology Solutions , Twitter , Bimekizumab Treatment Improves Health , Ucb Inc , Drug Administration , Group Of Companies , European Union Eu Economic Area , Us Immunology Communications , Source Ucb Inc , Executive Vice President , Psoriatic Arthritis , Active Psoriatic Arthritis , Week Efficacy , Safety Results , Active Reference , Inadequate Response , Tumor Necrosis Factor Inhibitors , Treatment Improves Health Related Quality , Active Psa , Week Results From Two Phase , Disease Activity Assessed , Composite Endpoints , Week Results , Treatment Results , Two Phase , Greater Improvements , Patient Centric Measures , Physical Function , Maintains Improvements , Efficacy Endpoints , Consistent Safety Profile Through , Non Radiographic Axial Spondyloarthritis , Ankylosing Spondylitis , Two Parallel Phase , Improves Signs , Including Inflammation , Active Non Radiographic Axial Spondyloarthritis , Active Ankylosing Spondylitis , Safety From , Placebo Controlled , Improves Key Patient Reported Symptoms , Axial Spondyloarthritis Including Spinal Pain , Improves Physical Function , Health Related Quality , Axial Spondyloarthritis , Results From Two Phase , Increasingly Stringent Clinical Response Criteria , Lower Levels , Patients With Active Axial Spondyloarthritis , Exploratory Analysis , Clinical Response , Certolizumab Pegol Treatment , Active Axial , Term Clinical Outcomes , Active Non , Radiographic Axial Spondyloarthritis Stratified , C Reactive Protein , Preliminarily Proposed , Sacroiliac Joints , Axial Spondyloarthritis Patients , European Union , European Economic Area , Euronext Brussels , Product Characteristics ,